Interagency Collaboration for Patient-Centered Antibacterial Drug Development.
Publication
, Journal Article
Howard-Anderson, J; Doernberg, SB; Dixon, D; Gopinath, R; Rubin, D; Kinamon, T; Kim, P; Collyar, D; Cosgrove, SE; Fowler, VG; Chambers, HF ...
Published in: Clin Infect Dis
August 6, 2025
This manuscript presents key advances of the Antibacterial Resistance Leadership Group (ARLG) Innovations Task Force, a collaboration focused on improving endpoints for registrational trials of antibacterial drugs, including health-related quality-of-life measures, for common acute infections. This group includes members from the United States Food and Drug Administration, National Institutes of Health, academia, industry, and patient representatives to amplify patient voices and ensure that the endpoints are meaningful to how patients feel, function, and survive.
Duke Scholars
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
August 6, 2025
Volume
81
Issue
Supplement_1
Start / End Page
S11 / S15
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Quality of Life
- Patient-Centered Care
- Microbiology
- Humans
- Drug Development
- Bacterial Infections
- Anti-Bacterial Agents
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Howard-Anderson, J., Doernberg, S. B., Dixon, D., Gopinath, R., Rubin, D., Kinamon, T., … Boucher, H. W. (2025). Interagency Collaboration for Patient-Centered Antibacterial Drug Development. Clin Infect Dis, 81(Supplement_1), S11–S15. https://doi.org/10.1093/cid/ciaf298
Howard-Anderson, Jessica, Sarah B. Doernberg, Dennis Dixon, Ramya Gopinath, Daniel Rubin, Tori Kinamon, Peter Kim, et al. “Interagency Collaboration for Patient-Centered Antibacterial Drug Development.” Clin Infect Dis 81, no. Supplement_1 (August 6, 2025): S11–15. https://doi.org/10.1093/cid/ciaf298.
Howard-Anderson J, Doernberg SB, Dixon D, Gopinath R, Rubin D, Kinamon T, et al. Interagency Collaboration for Patient-Centered Antibacterial Drug Development. Clin Infect Dis. 2025 Aug 6;81(Supplement_1):S11–5.
Howard-Anderson, Jessica, et al. “Interagency Collaboration for Patient-Centered Antibacterial Drug Development.” Clin Infect Dis, vol. 81, no. Supplement_1, Aug. 2025, pp. S11–15. Pubmed, doi:10.1093/cid/ciaf298.
Howard-Anderson J, Doernberg SB, Dixon D, Gopinath R, Rubin D, Kinamon T, Kim P, Collyar D, Cosgrove SE, Fowler VG, Chambers HF, Evans SR, Holland TL, King HA, Boucher HW. Interagency Collaboration for Patient-Centered Antibacterial Drug Development. Clin Infect Dis. 2025 Aug 6;81(Supplement_1):S11–S15.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
August 6, 2025
Volume
81
Issue
Supplement_1
Start / End Page
S11 / S15
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Quality of Life
- Patient-Centered Care
- Microbiology
- Humans
- Drug Development
- Bacterial Infections
- Anti-Bacterial Agents
- 3202 Clinical sciences